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Introduction: The incidence of achondroplasia is very low, and the birth of two or more consecutive babies with
achondroplasia to unaffected parents is a rarity. We report a rare case of recurrent achondroplasia in babies of
unaffected parents.
Case presentation: A 29-year-old Nigerian Igbo woman who has had three consecutive dead achondroplastic
babies presented at a gestational age of 31 weeks with a two-hour history of drainage of liquor and vaginal
bleeding. Neither she nor her husband had features of achondroplasia. Fundal height was compatible with the
gestational age. Fetal heart activity was present. An abdominal ultrasound examination showed a viable fetus with
short long bones, oligohydramnios, and a fundal placenta with a small retroplacental blood clot. Our patient was
stabilized and had an emergency Cesarean section for grade 1 abruptio placentae. A live male baby with Apgar
scores of 4 at one minute and 5 at 10 minutes was delivered. The baby had classic features of achondroplasia and
died shortly after birth.
Conclusions: To the best of our knowledge, this is the first reported case of recurrent achondroplasia in siblings of
unaffected parents in Nigeria. Management is challenging, and the outcomes of future pregnancies appear bleak.
However, proper counseling and follow-up are needed. There is also a need to establish preconception clinics and
facilities for prenatal genetic diagnosis and gene therapy in developing countries.Introduction
Achondroplasia is a genetic disorder of bone growth
and usually is evident at birth. It affects about one in
10,000 to one in 30,000 births and occurs in all races
and in both sexes [1]. It is the most common of a
group of growth defects characterized by abnormal
body proportions: short stature with disproportionate
short limbs [1,2].
It is caused by a mutation in a gene, fibroblast growth
factor receptor 3 (FGFR3), that is located in chromo-
some 4 (chromosomal locus 4p16.3), which is one of the
physiological regulators of linear bone growth [3,4]. The
mutation leads to excessive tyrosine kinase activity in
the receptors within the cartilaginous growth plate,
thereby inhibiting bone growth [5]. All bones that form
by endochondral ossification are affected, but bones that
form by membranous ossification are not affected, thus
allowing the skull vault to develop normally [3,4].* Correspondence: tigwegbe@yahoo.com
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trait with complete penetrance; all individuals with the
trait must have achondroplasia [3-5]. Inheritance of
one abnormal gene from each parent results in severe
skeletal abnormalities that may lead to early death (in
the fatal form of the disease). Parents of children with
achondroplasia resulting from a new mutation usually
are of normal height. Typically, these parents have no
other children with achondroplasia, and the chances
of their having a second affected child are less than
1% [6,7].
In more than 80% of cases, achondroplasia is not
inherited but results from a new or de novo dominant
mutation that occurs in the egg or sperm cell that forms
the embryo with a mutation rate estimated to be
0.000014 per gamete per generation [2,5]. A reoccur-
rence of this, especially in a non-achondroplastic couple,
is a rare and perplexing event, and the outcome of fu-
ture pregnancies appears bleak, as in the case reported
here.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A 29-year-old, Nigerian Igbo woman who had not pre-
registered at a hospital and who was in her fourth preg-
nancy presented at the labor ward at a gestational age
of 31 weeks with a two-hour history of spontaneous
drainage of liquor and subsequent vaginal bleeding. She
has had three consecutive deliveries of dead achondro-
plastic babies and had no living child. The vaginal
bleeding was moderate, and there was no dizziness or
fainting spells. There was no history of bleeding from
other sites, abdominal pain, trauma, fever, dysuria, vagi-
nal discharge, or chronic cough. She was not known to
be hypertensive or diabetic. She had no history of sur-
gery or radiation exposure. There was no family history
of achondroplasia.
The index pregnancy was spontaneously conceived
and was supported by her husband, who was a 34-year-
old trader. She booked at a gestational age of 13 weeks
in a private hospital and her booking parameters were
said to be normal. There was no previous ultrasound
examination, and the pregnancy had been uneventful
until presentation. She was referred to the teaching hos-
pital because of the spontaneous rupture of membranes
(SROM) and vaginal bleeding.
Her first confinement was in 2005. She had SROM at
a gestational age of 30 weeks and delivered a live achon-
droplastic female baby in a private hospital. However,
the baby died a few minutes after delivery.
Her second confinement was in January 2008. She had
ultrasound diagnoses of gross fetal abnormality and
achondroplasia in a private hospital. The pregnancy was
consequently terminated by using intra-vaginal miso-
prostol at a gestational age of 25 weeks.
The third confinement was in January 2009. She
booked at the teaching hospital at a gestational age of
28 weeks. Her hemoglobin genotype is AA and her
blood group is O Rhesus D-positive. The result of a ven-
eral disease research laboratory test was non-reactive.
The results of a test for human immunodeficiency virus
I and II were negative. The results of fasting blood sugar
and two-hour postprandial tests were normal. She
received one course each of intermittent preventive ther-
apy for malaria and tetanus toxoid at 28 weeks of gesta-
tion. An abdominal ultrasonography scan at 30 weeks
revealed features of fetal achondroplasia and polyhy-
dramnios. She had a premature rupture of membranes
at 31 weeks of gestation. She had an intra-uterine fetal
death while on conservative management and subse-
quently a spontaneous vertex delivery of a fresh stillborn
boy that weighed 1.2kg. The following features were
noted: short upper and lower limbs, a relatively large
head circumference, a conjoined and patent anterior
fontanelle, and a gangrenous intestine. An anatomical
diagnosis of achondroplasia was made at autopsy.A clinical examination revealed a woman who was in
painful distress, afebrile, and anicteric but pale. There
was no pedal edema. Her height was 1.68m and her
body weight was 60kg. The height of her husband was
1.70m. Neither had any features of achondroplasia. Her
abdomen was enlarged and moved with respiration.
There was generalized tenderness in her abdomen. The
symphysiofundal height was 28cm. The abdomen was
hard, and the fetal parts were not easily discernible. The
fetal heart rate was 160 beats per minute.
The urgent packed cell volume was 30%, and the
results of urine analysis and clotting time were normal.
The transabdominal ultrasound examination at the labor
ward revealed oligohydramnios and a viable fetus with
achondroplasia. The placenta was fundal with small ret-
roplacental blood collection. A diagnosis of abruptio pla-
centae grade 1 was made. Our patient and her husband
were counseled on the diagnosis and options of delivery.
They consented to delivery via Cesarean section.
The intra-operative findings included an achondro-
plastic live male baby who had Apgar scores of 4 at one
minute and 5 at 10 minutes and who weighed 1.1kg.
The baby had a relatively large head circumference, nor-
mal length of trunk, short limbs, and broad hands and
feet (rhizomelic) as well as a protruding tongue, a large
defect joining anterior and posterior fontanelles, hepa-
tosplenomegaly, and low-set ears. However, the baby
died 30 minutes after birth. The estimated blood loss
was 400mL, excluding a retroplacental clot of about
100mL. Her post-operative recovery was satisfactory. A
diagnosis of recurrent achondroplasia was made.
Discussion
This is the first reported case of de novo achondroplasia,
which is the most common of the human chondrodys-
plasias, in our center [6]. Few cases of recurrent sporadic
(de novo) achondroplasia have been reported [7,8]. The
term was coined over a century ago to distinguish indivi-
duals with a disproportionate short stature from indivi-
duals with a proportionate short stature.
The pathophysiology of the genetic mutation for de
novo achondroplasia remains hypothetical. Fryns et al.
[9] had suggested germinal mosaicism, and Opitz [10]
suggested unstable premutation with reduced pene-
trance. A study has also shown that advanced paternal
age, particularly over 35 years, strongly correlates with
achondroplasia and certain other autosomal dominant
conditions caused by new mutations [11]. This was not
applicable in the reported case since both parents were
younger than 35 years old.
Prenatal genetic diagnosis may be made through am-
niocentesis and a chorionic villus sample. Second tri-
mester ultrasonography also may be diagnostic. The
ultrasound features of fetal achondroplasia include a
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diameter, abdominal circumference and foot length
within normal limits, a femur-to-foot length ratio of less
than 0.87, and a femur length-to-abdominal circumfer-
ence ratio of less than 0.18. In high-risk couples, a com-
bination of ultrasongraphy and genetic studies would
establish an accurate diagnosis, which is required for ap-
propriate counseling [12]. A misdiagnosis chance of
7.8%, based on sonographic biometric data, has been
reported [13]. Owing to the routine prenatal ultrasound
examination in developed countries, achondroplasia of
many affected fetuses is recognized in the third trimester
of pregnancy and so families can be prepared for the
birth of an affected child.
The features of achondroplasia can easily be identified
clinically and radiologically at birth and infancy [6,7].
The rhizomelic appearance is pathognomonic [6]. Fea-
tures include a long narrow trunk with very short limbs,
macrocephaly with frontal bossing, hyperextensible
joints, abducted hip, moderate hypotonia, and delayed
milestones. The radiological features include a large cra-
nium with a protuberant forehead, short long bones, and
a V-shaped appearance of distal femoral epiphyses. How-
ever, for about 20% of affected individuals, achondropla-
sia may not be recognized at birth [2]. In doubtful cases,
genetic testing using a blood sample may be done. In the
case reported, diagnosis was made by using the physical
features and autopsy result of the previous baby. Genetic
studies could be diagnostic and therapeutic. However,
such facilities are not available in our center.
The management of recurrent achondroplasia is more
difficult and challenging in resource-poor countries. This
is because of the unavailability of tools for genetic diag-
nosis and therapy. Human growth hormone and osteoto-
mies (surgical limb lengthening) had been used with
very limited success to increase stature in children and
are no longer recommended [7].
Some recent therapeutic innovations are based on the
pathogenesis of achondroplasia. With emerging know-
ledge of the molecular pathogenesis, interest has begun
to shift to therapy intended to counter the effects of the
overactive receptor. Although the precise mechanism is
not known, the stabilization of FGFR3 dimerization
caused by the mutation is believed to enhance the kinase
activity of the receptor. Strategies involve inhibition of
the FGFR3 receptor activity by using chemical agents or
receptor-blocking antibodies [14]. These agents would
downregulate the excessive tyrosine kinase activity of the
receptors. Another molecular therapy involves C-type
natiuretic peptide (CNP), which because of its effects on
fluid and electrolyte balance and vascular tone is being
evaluated as a therapeutic agent for certain cardiovascu-
lar diseases. Since CNP has recently been shown to
downregulate fibroblast growth factor-induced activationof mitogen-activated protein kinase signaling pathways
in growth plate chondrocytes and to counteract the
effects of the achondroplasia mutation in mice, it has
been suggested as a possible treatment for achondropla-
sia in humans [15].
All of these therapeutic approaches are in the early
stages of development. However, they are promising and
will reach the clinical trial phase of development. In
developing countries where gene therapy is not available,
donor insemination, ovum donation, and child adoption
may be options for the management of recurrent de
novo achondroplasia.
Conclusions
This presentation highlights one of the genetic problems
that could cause recurrent pregnancy loss and dilemmas
in management in our environment. In spite of the em-
phasis on reducing maternal mortality and infections,
there is also a need to establish preconception clinics
and facilities for prenatal genetic diagnosis and gene
therapy in developing countries.
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